Not Signed In - La Jolla Pharmaceutical Announces Continued Enrollment Progress And Enhancements To International Phase 3 Riquent(R) Study
Fri, 02 Feb 2007 08:00 AM EST
... La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced its continued progress in enrolling patients in its Phase 3 clinical trial of Riquent(R) (abetimus sodium) for the treatment of lupus renal disease. [click link for full article] ...
Related Topics
- International Health
- Tolterodine
- Yoga
- Phenylephrine and Guaifenesin ER Tablets
- Guaifenesin and Potassium Guaiacolsulfonate
- Phenylephrine and Guaifenesin Capsules
- Psychopharmacology
- Smoking Cessation and Continued Risk in Cancer Patients
- Rue
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Pseudoephedrine and Guaifenesin ER
- Propranolol
- Retinoblastoma
- Peritoneal Dialysis
- Radiation Studies
- Diltiazem ER
- CHF
- Drug Information
- Pseudoephedrine and Guaifenesin
email this page
print this page
bookmark this page
feedback on this page
